A win for some patients with HER2-negative metastatic breast cancer

https://www.facingourrisk.org/XRAY/treatment-for-HER2-low-metastatic-breast-cancer

Full article: https://www.nejm.org/doi/full/10.1056/NEJMoa2203690

A drug used to treat HER2-positive breast cancer improved survival in people with metastatic breast cancers that were previously considered HER2-negative. These results change practice guidelines for metastatic breast cancer and reclassify HER2 tumor marker status as “HER2-low” to guide treatment. (Posted 7/18/22)

Update: On 08/05/2022 the FDA approved Enhertu to treat people with metastatic, HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or who developed disease recurrence during or within six months of completing chemotherapy. Enhertu is also approved for treatment of people with metastatic HER2-positive breast cancer who progressed after prior anti-HER2 treatment. Este artículo está disponible en español.

Questions To Ask Your Health Care Provider

Was my tumor tested for HER2 using a test that measures HER2-low? If yes, what was the HER2 score? If not, can it be tested now?
Is Enhertu an option for me?
What are the risks and benefits associated with Enhertu?
Will my insurance cover the cost of additional HER2 testing and Enhertu?

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.